Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Disc Medicine Inc (IRON)

Disc Medicine Inc (IRON)
35.00 x 1 54.99 x 4
Post-market by (Cboe BZX)
45.15 +1.14 (+2.59%) 04/23/25 [NASDAQ]
35.00 x 1 54.99 x 4
Post-market 45.15 unch (unch) 16:05 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
45.09
Day High
47.58
Open 45.54
Previous Close 44.01 44.01
Volume 414,118 414,118
Avg Vol 587,366 587,366
Stochastic %K 68.70% 68.70%
Weighted Alpha +15.17 +15.17
5-Day Change +3.84 (+9.30%) +3.84 (+9.30%)
52-Week Range 25.64 - 68.73 25.64 - 68.73
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,521,382
  • Shares Outstanding, K 34,569
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,360 K
  • EBIT $ -130 M
  • EBITDA $ -135 M
  • 60-Month Beta 0.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.83

Options Overview Details

View History
  • Implied Volatility 58.10% ( -7.38%)
  • Historical Volatility 83.31%
  • IV Percentile 17%
  • IV Rank 22.20%
  • IV High 97.85% on 04/08/25
  • IV Low 46.76% on 02/20/25
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,187
  • Volume Avg (30-Day) 589
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 4,780
  • Open Int (30-Day) 3,482

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 5
  • High Estimate -0.87
  • Low Estimate -1.21
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +9.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.82 +46.50%
on 04/09/25
Period Open: 52.24
54.59 -17.29%
on 03/24/25
-7.09 (-13.57%)
since 03/21/25
3-Month
30.82 +46.50%
on 04/09/25
Period Open: 56.99
59.25 -23.80%
on 01/27/25
-11.84 (-20.78%)
since 01/23/25
52-Week
25.64 +76.07%
on 04/26/24
Period Open: 27.00
68.73 -34.31%
on 11/11/24
+18.15 (+67.22%)
since 04/23/24

Most Recent Stories

More News
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

IRON : 45.15 (+2.59%)
Disc Medicine to Participate in Upcoming Investor Conferences

IRON : 45.15 (+2.59%)
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

IRON : 45.15 (+2.59%)
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IRON : 45.15 (+2.59%)
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

IRON : 45.15 (+2.59%)
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

IRON : 45.15 (+2.59%)
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

IRON : 45.15 (+2.59%)
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

IRON : 45.15 (+2.59%)
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

IRON : 45.15 (+2.59%)
Disc Medicine Reports Positive Phase 1b Results for DISC-0974 in Myelofibrosis Anemia and Initiates Phase 2 Study

Disc Medicine's DISC-0974 shows positive hematologic responses in myelofibrosis anemia, leading to a Phase 2 trial initiation.Quiver AI SummaryDisc Medicine, Inc. announced positive results from a Phase...

IRON : 45.15 (+2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

See More

Key Turning Points

3rd Resistance Point 49.28
2nd Resistance Point 48.43
1st Resistance Point 46.79
Last Price 45.15
1st Support Level 44.30
2nd Support Level 43.45
3rd Support Level 41.81

See More

52-Week High 68.73
Fibonacci 61.8% 52.27
Fibonacci 50% 47.19
Last Price 45.15
Fibonacci 38.2% 42.10
52-Week Low 25.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective